1. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 2015;25:567-610.
[CROSSREF] [PUBMED] [PMC]
2. Trimboli P, Treglia G, Guidobaldi L, Romanelli F, Nigri G, Valabrega S, et al. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. Clin Endocrinol (Oxf) 2015;82:280-285.
[CROSSREF] [PUBMED]
3. Pusztaszeri MP, Bongiovanni M, Faquin WC. Update on the cytologic and molecular features of medullary thyroid carcinoma. Adv Anat Pathol 2014;21:26-35.
[CROSSREF] [PUBMED]
4. Trimboli P, Giovanella L, Crescenzi A, Romanelli F, Valabrega S, Spriano G, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck 2014;36:1216-1223.
[CROSSREF] [PUBMED]
5. Trimboli P, Giovanella L. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature. Clin Chem Lab Med 2015;53:1507-1514.
[CROSSREF] [PUBMED] [PDF]
6. Trimboli P, Seregni E, Treglia G, Alevizaki M, Giovanella L. Procalcitonin for detecting medullary thyroid carcinoma: a systematic review. Endocr Relat Cancer 2015;22:R157-R164.
[CROSSREF] [PUBMED]
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6:e1000100.
[CROSSREF] [PUBMED] [PMC]
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
[CROSSREF] [PUBMED]
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-560.
[CROSSREF] [PUBMED] [PMC]
10. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455-463.
[CROSSREF] [PUBMED]
11. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-536.
[CROSSREF] [PUBMED]
12. Bihan H, Becker KL, Snider RH, Nylen E, Vittaz L, Lauret C, et al. Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid 2003;13:819-822.
[CROSSREF] [PUBMED]
13. Bolko P, Manuszewska-Jopek E, Michalek K, Wasko R, Jaskula M, Sowinski J. Efficacy of procalcitonin measurement in patients after total thyroidectomy due to medullary thyroid carcinoma. Arch Immunol Ther Exp (Warsz) 2003;51:415-419.
[PUBMED]
14. Algeciras-Schimnich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009;94:861-868.
[CROSSREF] [PUBMED] [PDF]
15. Kaczka K, Mikosinski S, Fendler W, Jalocha-Kaczka A, Pomorski L. Can procalcitonin be useful for medullary thyroid cancer? Endokrynol Pol 2010;61:430-436.
[PUBMED]
16. Kaczka K, Mikosinski S, Fendler W, Celnik A, Pomorski L. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Adv Clin Exp Med 2012;21:169-178.
[PUBMED]
17. Walter MA, Meier C, Radimerski T, Iten F, Kranzlin M, Muller-Brand J, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer 2010;116:31-40.
[CROSSREF] [PUBMED]
18. Kratzsch J, Petzold A, Raue F, Reinhardt W, Brocker-Preuss M, Gorges R, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem 2011;57:467-474.
[CROSSREF] [PUBMED] [PDF]
19. Trimboli P, Lauretta R, Barnabei A, Valabrega S, Romanelli F, Giovanella L, et al. Procalcitonin as a postoperative marker in the follow-up of patients affected by medullary thyroid carcinoma. Int J Biol Markers 2018;33:156-160.
[CROSSREF] [PUBMED]
20. Giovanella L, Imperiali M, Ferrari A, Palumbo A, Lippa L, Peretti A, et al. Thyroid volume influences serum calcitonin levels in a thyroid-healthy population: results of a 3-assay, 519 subjects study. Clin Chem Lab Med 2012;50:895-900.
[CROSSREF] [PUBMED] [PDF]
21. Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf) 2004;61:299-310.
[CROSSREF] [PUBMED]
22. Niccoli P, Conte-Devolx B, Lejeune PJ, Carayon P, Henry JF, Roux F, et al. Hypercalcitoninemia in conditions other than medullary cancers of the thyroid. Ann Endocrinol (Paris) 1996;57:15-21.
[PUBMED]
23. Iacobone M, Niccoli-Sire P, Sebag F, De Micco C, Henry JF. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 2002;26:886-890.
[CROSSREF] [PUBMED] [PDF]
24. Silva OL, Broder LE, Doppman JL, Snider RH, Moore CF, Cohen MH, et al. Calcitonin as a marker for bronchogenic cancer: a prospective study. Cancer 1979;44:680-684.
[CROSSREF]
25. Zaidi M, Moonga BS, Bevis PJ, Bascal ZA, Breimer LH. The calcitonin gene peptides: biology and clinical relevance. Crit Rev Clin Lab Sci 1990;28:109-174.
[CROSSREF] [PUBMED]
26. Fugazzola L, Pinchera A, Luchetti F, Iacconi P, Miccoli P, Romei C, et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994;9:21-24.
[CROSSREF] [PUBMED]
27. Becker KL, Snider RH, Silva OL, Moore CF. Calcitonin heterogeneity in lung cancer and medullary thyroid cancer. Acta Endocrinol (Copenh) 1978;89:89-99.
[CROSSREF] [PUBMED]
28. Goltzman D, Tischler AS. Characterization of the immunochemical forms of calcitonin released by a medullary thyroid carcinoma in tissue culture. J Clin Invest 1978;61:449-458.
[CROSSREF] [PUBMED] [PMC]
29. Austin LA, Heath H 3rd. Calcitonin: physiology and pathophysiology. N Engl J Med 1981;304:269-278.
[CROSSREF] [PUBMED]
30. Machens A, Lorenz K, Dralle H. Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer. J Clin Endocrinol Metab 2014;99:2986-2994.
[CROSSREF] [PUBMED] [PDF]
31. Giovanella L, Imperiali M, Piccardo A, Taborelli M, Verburg FA, Daurizio F, et al. Procalcitonin measurement to screen medullary thyroid carcinoma: a prospective evaluation in a series of 2,705 patients with thyroid nodules. Eur J Clin Invest 2018;48:e12934.
[CROSSREF] [PUBMED] [PMC]
32. Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis. A journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004;89:1512-1525.
[CROSSREF] [PUBMED]
33. Novotny AR, Luppa P, Rosenberg R, Schneider H, Maak M, Bartels H, et al. Procalcitonin can be used for monitoring sepsis in patients with medullary thyroid carcinoma. Thyroid 2009;19:1287-1289.
[CROSSREF] [PUBMED]